Intellia Therapeutics’ (NTLA) “Market Outperform” Rating Reiterated at Citizens Jmp

Citizens Jmp reissued their market outperform rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a research report released on Tuesday morning,Benzinga reports. Citizens Jmp currently has a $30.00 price objective on the stock.

Other equities research analysts have also recently issued research reports about the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $49.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, June 16th. Chardan Capital boosted their price target on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. Morgan Stanley increased their price objective on shares of Intellia Therapeutics from $11.00 to $15.00 and gave the company an “equal weight” rating in a report on Monday, April 27th. Wolfe Research lowered shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 target price on the stock. in a research note on Wednesday, July 15th. Finally, Sanford C. Bernstein boosted their target price on Intellia Therapeutics from $13.00 to $17.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have issued a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $21.15.

Intellia Therapeutics Stock Down 0.6%

NTLA opened at $13.11 on Tuesday. The company has a market cap of $1.84 billion, a PE ratio of -3.90 and a beta of 1.81. Intellia Therapeutics has a twelve month low of $7.95 and a twelve month high of $28.25. The company has a 50-day moving average price of $13.31 and a 200 day moving average price of $13.38.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.80). The company had revenue of $7.66 million for the quarter, compared to analysts’ expectations of $12.98 million. Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.Intellia Therapeutics’s revenue was down 46.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.98) EPS. As a group, sell-side analysts expect that Intellia Therapeutics will post -3.21 earnings per share for the current year.

Insider Buying and Selling

In other news, CAO Michael P. Dube sold 2,641 shares of Intellia Therapeutics stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total transaction of $44,315.98. Following the completion of the sale, the chief accounting officer directly owned 66,886 shares of the company’s stock, valued at approximately $1,122,347.08. The trade was a 3.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total transaction of $84,186.00. Following the transaction, the executive vice president owned 156,286 shares of the company’s stock, valued at approximately $2,813,148. The trade was a 2.91% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.50% of the stock is owned by insiders.

Institutional Trading of Intellia Therapeutics

Institutional investors have recently bought and sold shares of the business. Comerica Bank lifted its stake in Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after buying an additional 901 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of Intellia Therapeutics during the second quarter worth about $26,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Intellia Therapeutics during the third quarter worth about $30,000. Freestone Grove Partners LP acquired a new position in Intellia Therapeutics in the 2nd quarter valued at about $33,000. Finally, Nykredit A S acquired a new position in Intellia Therapeutics in the 2nd quarter valued at about $33,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.